

# Balaglitazone

## Catalog No: tcsc1441



### Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



### Specifications

**CAS No:**

199113-98-9

**Formula:**

$C_{20}H_{17}N_3O_4S$

**Pathway:**

Cell Cycle/DNA Damage

**Target:**

PPAR

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq$  500 mg/mL (1264.45 mM)

**Alternative Names:**

DRF 2593;NN 2344

**Observed Molecular Weight:**

395.43


## Product Description

Balaglitazone is a selective partial **PPAR $\gamma$**  agonist with an **EC<sub>50</sub>** of 1.351  $\mu$ M for human **PPAR $\gamma$** .

IC50 & Target: EC50: 1.351  $\mu$ M (Human PPAR $\gamma$ )<sup>[1]</sup>

***In Vitro:*** Balaglitazone is a selective partial PPAR $\gamma$  agonist with an EC<sub>50</sub> of 1.351  $\mu$ M<sup>[1]</sup>. Balaglitazone (5-100  $\mu$ M) has equal cytotoxicity towards K562 and K562/DOX cells. Balaglitazone decreases doxorubicin cytotoxicity in K562 and K562/DOX cells, with IC<sub>50</sub>s of 0.117  $\mu$ M and 0.53  $\mu$ M, respectively. Balaglitazone reverses multidrug resistance (MDR) in K562/DOX cells. Balaglitazone (25  $\mu$ M) increases Rh123 accumulation in K562/DOX cells, but does not increase MFI in K562 cells. Balaglitazone downregulates P-gp expression in K562/DOX cells, and such effects are via upregulation of PTEN in K562/DOX cells, and be abolished by PTEN inhibition<sup>[2]</sup>.

***In Vivo:*** Balaglitazone (3 mg/kg, p.o.) shows antihyperglycaemic activity in fully diabetic and insulin resistant db/db mice, and is more potent than the full PPAR $\gamma$  agonist rosiglitazone<sup>[1]</sup>. Balaglitazone (10 mg/kg, p.o.) suppresses overall glucose, decreases insulin levels, and increases bodyweight in male diet-induced obese rats, and such effects are equal to that of 30 mg/kg pioglitazone<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!